Edmund Folefac

Edmund Folefac's research focuses on clinical trials for genitourinary cancers, particularly metastatic prostate cancer and advanced renal cell carcinoma (kidney cancer). Much of the work involves testing combination treatments—such as radium-223 (a bone-targeting radioactive drug) with PARP inhibitors like olaparib, or immunotherapy combinations like nivolumab plus ipilimumab—to improve outcomes for patients with advanced disease. The work is largely clinical and trial-based, often reported through conference abstracts and clinical oncology journals.

Publication output rose sharply around 2019-2021 and has since moderated to a steadier annual pace over the past few years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026